Therapeutic
successes following treatment of murine tumors with tumor necrosis factor-a (TNF) have not been easily applied to clinical oncology because the concentrations ofTNF required in humans induces systemic toxicity. This has led us to identify mediators which could sensitize tumors to the effects ofTNF, permitting administration of lower doses and possible realization of the therapeutic potential of this cytokine. Our study reports the ability of a novel cytokine, endothelial-monocyte-activating polypeptide 11 (EMAP 11), to sensitize initially resistant murine and human tumors to TNF-induced regression employing a murine modelo Recombinant (r) EMAP 11 was purified from Escherichia coli transformed with a plasmid expressing mature EMAP 11. The B16 melanoma, raised in C57BU6 mice, or ahuman fibrosarcoma (HT-1080), grown in immunocompromised mice, was injected intratumorally with either vehicle or rEMAP Il/heattreated EMAP 11 (50-100 jJ-g) followed by systemic TNF/heat-treated TNF (5 jJ-g) and assessed for tumor volume, hemorrhage, and histologic appearance. Both the B16 melanoma and the HT-1080 human fibrosarcoma underwent thrombohemorrhagic and acute inflammatory changes concomitant with regression or significantly slowed growth after Administration ofintratumor EMAP 11 followed by systemic TNF. Omission or inactivation of either cytokine abrogated this effect. These results demonstrate that local treafment of certain tumors with EMAP 11 results in enhanced susceptibility to TNF-mediated induction of thrombohemorrhage and regression. @ 1996 Academic Press, Inc.
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I1 example of such an experimental neoplasm; histologic appearance of the tumor indicates foci of host effector cells, zones ofnecrosis, and, at later times, spontaneous regression [1] [2] [3] [4] . The striking response of meth A tumor vasculature following infusion of tumor necrosis factor-a (TNF) algo distinguishes the neoplasm from normal host tissues. Intravenous administration oflow amounts ofTNF (3-5 jJ;g) results in localized thromboBis, leukostasis, and hemorrhage in tumor neovessels leading to ischemic necrosis of the tumor [2-4]. These observations have led us to identify factors made by meth A tumor cells which have the capacity to induce activation of endothelial cells, monocytes, and polymorphonuclear leukocytes, which may explain the tumor thrombohemorrhage induced by TNF [5] [6] [7] [8] .
Our recent studies have led to the isolation and cloning of endothelial-monocyte-activating polypeptide (EMAP) II from conditioned media of meth A cells in culture [7, 8] . Analysis of the cDNA indicates that EMAP II is a novel polypeptide which is not a member of previous cytokine or growth factor families. EMAP II is synthesized as an ~34-kDa precursor which is cleaved to an 18-to 22-kDa mature form, the latter released by meth A tumor cells. Our previous studies have shown that mature EMAP II activates endothelial cells (induction of tissue factor procoagulant activity, expression ofleukocyte adherence molecules P-selectin and E-selectin), leukocytes (induction of chemotaxis and degranulation), and monocytes (generation of cytokines, tissue factor, and induction of cell migration) at picomolar concentrations. The presence of such a mediator in the bed of meth A tumors suggested that it could prime the vasculature for the exaggerated response to TNF displayed by these neoplasms. If this hypothesis was correct, wereasoned that local injection of EMAP II into the bed of a tumor initially not sensitive to TNF should prime the vasculature, resulting in subsequent sensitivity to low concentrations of TNF.
INTRODUCTION
The study oí immunogenic múrine tumors provides a means through which a host can mount an effective jmmune/infiammatory response resulting in destruction oí the neoplastic lesiono Murine methylcholanthrene A (meth A)l fibrosarcomas are a well-studied Murine footpad model. Footpads of Balb/c mice (6-12 weeks) were injected with 30-40 JlI ofEMAP 11 in phosphate-buffered saline (50 Jlg), the same amount ofEMAP 11 following heat inactivation by boiling for 30 min, or phosphate-buffered saline alone, as described [12] [13] [14] . After 6 hr, footpads were harvested, fixed in buffered formalin (10%), decalcified, and embedded in paraffin. Sections were stained with hematoxylin and eosin.
Treatment oftumors withEMAP 11 and TNF. Bl6/F01 melanoma cells, which forro poorly immunogenic tumors [16] , were used to produce tumors in C57BU6 rice by intradermal injection of 1 x 106 cells into the dorsal skin of each animal. Human fibrosarcoma cells [17] were used to establish tumors in severe combined immunodeficiency (SCID) mice. When tumors reached 0.5-1.0 cm in diameter, they were directly injected using a 30-gauge needle with vehicle solution (phosphate-buffered saline with bovine serum albumin, 0.1%), EMAP 11 (50 and 100 Jlg in the vehicle, respectively, for B16 and human fibrosarcoma), or heat-treated EMAP 11 (50-100 Jlg). Alternatively, tumors were treated locally with EMAP 11 or heat-treated EMAP 11 followed by intravenous injection of TNF (5 Jlg) or heattreated TNF (5 Jlg) 18 hr later. Purified, recombinant human TNFa was generously provided by Knoll Pharmaceuticals (Whippany, NJ). Six hours after the injection, animals were sacrificed and tumors were excised for pathologic analysis after fixation in buffered formalin (10%). Where indicated, tumor volume was calculated from caliper measurements of length, width, and height, according to the formula for a spherical segment, V = 7rh(h2 + 3a2)/6, where h is the height of the segment, a is (length+width)/2, and Vis the volume [17] . Tumor tissue was analyzed histologically following formaldehyde fixation and paraffin embedding by hematoxylin and eosin staining, and immunohistochemically using anti-rat fibrin antiserum [18] and alkaline phosphatase-conjugated secondary antibody to visualize sites of binding of the primary antibody.
Statistical analysis. A repeated measures ANOVA [37] was used to analyze the tumor-volume data. A logarithmic transformation on the tumor variable "volume" was used to normalize the data to satisfy ANOVA's assumption of normality. The null hypothesis that the group-over-time interaction (!.e., that the volume changes across time are the same for subjects in both groups) was tested by Hotelling's t2 test-the multivariate analogue ofStudent's t test for two independent groups. duced SDS-PAGE (Fig. lA) , displaying Mr ~20 kDa. That this material with the expected apparent molecular weight on SDS-PAGE was EMAP II was further demonstrated by immunoblotting with antibody raised to EMAP II (Fig. lB) . Material derived from both reduced and nonreduced SDS-PAGE, following electrophoretic transfer to nitrocellulose membranes, showed a single immunoreactive band corresponding to migration of the major protein bando Host response elicited by rEMAP 11 in the murine footpad modelo Murine footpads have been used as a model to characterize the inflammatory and edematous response to a range of inflammatory agents [12, 13] . In a previous study, we demonstrated that EMAP II derived from meth A-induced murine fibrosarcomas elicited swelling and inflammation in the murine footpad [14] . As an initial check on the in vivo activity of preparations ofrEMAP II, its effects were tested in this modelo Footpads injected with rEMAP II demonstrated vascular congestion with leukostasis, tissue infiltration by leukocytes, and edema (Fig. 2B ) compared with controls receiving the same amount ofheat-inactivated rE-MAP II ( Fig. 2A ; appearance ofthese footpads is identical to untreated or phosphate-buffered saline-treated controls, data not shown). The inflammatory response appeared to last about 24 hr, was accompanied by considerable soft tissue swelling and erythema, and then resolved completely (data not shown).
Effect of rEMAP 11 on tumors resistant to TNF -induced thrombohemorrhage. EMAP II was first isolated from meth A tumors, which are well known for their elicitation of an inflammatory/immune response resulting in a heterogeneous appearance, with areas of inflammation and necrosis [4] . Administration of a low dose of systemic TNF to mice bearing meth A tumors results in thrombohemorrhage, which has been characterized in detail and begins with evidence ofthrombosis and leukostasis in tumor vasculature [3, 4] . In view of the potent effE;ct of EMAP II to activate endothelial RFSULTS Characterization of rEMAP 11. rEMAP 11 used in these studies was homogeneous on reduced and nonre- cells, mononuclear phagocytes, and polymorphonuclear leukocytes in vitro and its phlogogenic properties in the murine footpad (see above), we considered the hypothesis that EMAP lI-induced inflammation might exert a negative effect on tumor growth. We reasoned that a tumor bed primed by the presence of EMAP II (with activated vasculature and inflammatory effector cells) might be tipped to overt thrombohemorrhage when systemic TNF was subsequently given. This hypothesiswas tested in murine models using the murine B16 melanoma in C57BU6 mice, and in the HT-1080 human fibrosarcoma in SCID mice.
Mice injected with B16 melanoma cells were allowed to establish tumors to a size ofO.5-1.0 cm in diameter. At this point, tumors were injected once with either rEMAP 11 (50-:100 Ji,g) or vehicle atolle intratumorally, human fibrosarcoma (HT -1080) in SCID mice, and then to follow the same protocol as with the murine B16 melanoma above, i.e., intratumoral injection of EMAP 11 followed by infusion of systemic TNF (Fig. 5) . Only tumors receiving active rEMAP 11 followed by TNF displayed suppression of tumor growth, in Fig. 5 , compared with tumors receiving vehicle followed by TNF. The same results were observed in other control groups in which rEMAP 11 was replaced by heat-inactivated rEMAP 11, tumors received only vehicle, or no treatment was administered. Histologic analysis of human fibrosarcomas treated with rEMAP IIfl'NF demonstrated extensive loss of tumor cells, hemorrhage, and an inflammatory infiltrate (Fig. 6B ) compared with controls ( Fig. 6A ; the same group shown in Fig. 5 ). No systemic toxicity was observed with any of these treatment regiments using rEMAP 11 and/or TNF. Effect ofrEMAP 11 and TNF on B16 melanomas: Changes in tumor volume. B16 melanomas were implanted into C57BU6 rice and allowed to reach a size ofO.5-1.0 cm in diameter. Tumors were then injected locally with a single dose of either rEMAP 11 (50 JLg; 100 JLI, n = 25) or vehicle alone (100 JLI, n = 22) followed by intravenous injection ofTNF (5 JLg; 100 JLI). Tumor volume was determined at the indicated times. The P value was determined for the group- ,,-" ", and no effect on tumor volume was detectable. Inorder to test OuT hypothesis, tumor-bearing mice were primed for TNF-induced tumor regression by local administration ofEMAP 11 using the following protocol: local injection of either rEMAP 11 (50-100 jlg) or heat-treated rEMAP 11 (50-100 jlg) followed 18 hr later by systemic TNF (5 jlg) or heat-treated TNF (5 jlg). Only animals receiving the combination of active rEMAP 11 and active TNF displayed significant suppression of tumor growth (Fig. 3) . Note that control animals receiving only one dose of cytokine, heat-inactivated cytokine, or saline alone demonstrated tumor growth comparable to the group designated as "vehicletTNF" in Fig. 3 . No systemic toxicity was observed in mice receiving any of these regimens of rEMAP 11 and TNF. Histologic studies showed that the initially homogeneous B16 melanoma (Fig. 4A )developed extensive aTeas of thrombohemorrhage and an acute inflammatory infiltrate in tumor-bearing mice receiving EMAP II/rNF (Fig. 4B) . Immunohistologié studies using an antibody selective for rodent fibrin displayed virtuallack of immunoreactivity in untreated tumors (Fig. 4C ) and difrUge fibrin staining which colocalized with an aTea of thrombohemorrhage in treated tumors (Fig. 4, compare  D and B) .
A major obstacle in extrapolation of murine data demonstrating TNF-induced tumor thrombohemorrhage and regression to humans has been that the higher concentrations of TNF required result in overt systemic toxicity [19, 20] . One approach to this problem has been development of an isolated limb perfusion system in which high concentrations of TNF can be administered without spilling into the systemic circulation [21, 22] . We hypothesized that another means of dealing with this problem would be sensitizing tumors to the effects ofTNF by local pretreatment with rEMAP 11. OUT initial experimental approach was to rai~e the Effect on tumor volume. Human fibrosarcomas, raised from HT-I080 cells, were implanted into SCID mice and allowed to reach a size of 0.5-1 cm in diameter. Tumors were then injected locally with a single dose of either rEMAP II (100 JLg; 100 JLI, n = 18) or vehicle alone (100 JLI, n = 20) followed by intravenous injection of TNF (5 JLg; 100 JLI). Tumor volume was determined at the indicated times. The P value was determined for the group-over-time interaction by repeated measures ANOV A (Hotelling's t2 test) . meth A tumor cells for the presence of agents which would activate endothelium, inducing expression ofthe procoagulant cofactor tissue factor, increasing vascular permeability, and leading to expression of cell adherence molecules. Three polypeptides were characterized from meth A-conditioned medium: EMAP 1, a 40-kDa polypeptide; the murine homolog of vascular endothelial growth factor; and EMAP 11 [5] [6] [7] . As EMAP 11 was a very potent perturbant of endothelial cell function and had an unique N-terminal sequence, our work has focused on its further characterization [7, 8] .
Molecular cloning indicated that the N-terminal sequence of EMAP 11 purified from meth A-conditioned medium actually arase from an internal portion of the molecule [8] . The deduced amino acid sequence predicted an ::",34-kDa proform of EMAP 11 which would be cleaved to yield an 18-to 22-kDa mature form with the predicted N-terminal sequence. This situation was reminiscent ofinterleukin 1{3, especially in view ofthe presence of an aspartic acid residue at the P1 position in EMAP 11 which suggested it might be a substrate for interleukin 1{3-converting enzyme (or a member of the emerging related family of sulfhydryl-dependent proteases) [8] . However, EMAP 11 displayed an unique sequence and only very limited homology to other cytokines. The current study, employing recombinant, mature EMAP 11, demonstrates that this material has the capacity to stimulate an acute inflammatory response and to prepare a local site for a subsequent exaggerated response to systemic TNF. The histologic picture of the tumor bed after administration of EMAP 11, followed by systemic TNF, indeed shares features with that observed in the Shwartzman reaction [28, 29] . This leads us to hypothesize that local production ofEMAP 11 may serve as a preparatory stimulus, which then promotes the triggering of a destructive inflammatory response when TNF, the provocative stimulus, is administered. Such a two-hit model could explain the consistent localizationofTNF effects to the tumor bed in meth A tumors; i.e., although intense thrombohemorrhage is occurring in the neoplasm, no evidence of thrombosis or other systemic toxicity is observed in normal tissues. This algo suggests why other tumors may show apparent resistance to TNF at doses not affecting the normal organs; without local production of a mediator which prime s the tumor bed, high concentrations of cytokine are required which would have an equal affect on normal and tumor tissues.
These data algo suggest the importance of understanding the molecular basis of EMAP lI's effects on cellular targets, especially in relation to TNF. In this context, we have exploited the biologic activity of Nterminal peptides from mature EMAP 11 to perform radioligand-binding studies [14] . Binding of1251-labeled EMAP lI-derived peptides was dose-dependent and saturable. Cross-linking studies with disuccinimidyl suberate indicated that 1251-EMAP 11 peptide specifically bound to monocytes became associated with an ::",73-kDa polypeptide. Competition studies demonstrated that unlabeled EMAP lI-derived peptide and full-Iength EMAP 11 were effective competitors, though murine TNF -a and interleukin la were noto Taken together, these data suggest that the cell surface recognition site for EMAP 11 is likely to be distinct from that for TNF, and have led to ongoing studies with the goal of isolating the EMAP 11 receptor. Thus, at the present time we do not have a molecular explanation for EMAP lI-induced enhancement of the TNF response of tumors, though it appears that the receptors for these two cytokines are distinct, and we have no lnowledge of a direct interaction between these two molecules. One important possibility for such an interaction concerns the potential for EMAP 11 to induce changes in expression of TNF receptors, an issue currently being explored.
The exploitation of a local immune/inflammatory response has precedent in prior work with anti-ganglioside antibodies which show selective binding to melanomas [30] . Administration of the antibodies resulted in a local inflammatory reaction at the site of their binding in the tumor bed, speculated to underlie tumor destruction. Another approach might algo be considered with EMAP 11, especially in view ofthe biologic activity of a peptide from the N-terminus of mature EMAP 11 [14] . We have found that a fragment as short as a heptapeptide from the N-terminus ofmature EMAP 11 actiyates polymorphonuclear leukocytes [14] . It is possible that conjugation of such a peptide to an appropriate immunogenic carrier, and its subsequent injection along with irradiated tumor cells, might stimulate an inflammatory response promoting tumor destruction, as has been observed in studies in which tumor cells were transfected to express immunostimulatory and inflammatory cytokines and administered locally to induce regression of the primary tumor [31] [32] [33] [34] .
One puzzling aspect of the biology of EMAP 11 concerns why a tumor would make such a molecule which does not appear to positively impact on tumor survival. The production of inflammatory cytokines by tumors is often balanced by expression of anti-inflammatory mediators, such as interleukin 10 [35] or soluble cytokine receptors [36] , which prevent the cytokines from gaining access to cell-associated receptors and evoking pathologic responses. In contrast, EMAP 11 activity was easily detectable in supernatants of meth A cells (where it is present at very low levels), and these conditioned media effectively activated host effector cells. This leads us to speculate that EMAP 11 could be a potent agent in settings outside oftumor biology where it might underlie inflammatory changes in a variety of tissue beds. Alternatively, it is possible that EMAP 11 has other properties, Jet to be identified, that do provide an advantage for the growtb/spread of tumors.
The current studies in a murine model indicate that therapy of murine and human tumors with EMAP 11 has the potential to impact negatively on tumor growth. Further studies will be required under a range of conditions and with multiple tumors to determine if these effects can be extrapolated to cancer patients. An important i~sue to explore will be identification of
